[
    {
      "Developer / Researcher": "Inovio Pharmaceuticals/Beijing Advaccine Biotechnology/VGXI Inc./ Richter-Helm BioLogics/Ology Bioservices",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "DNA-based",
      "Stage of Development": "Phase I",
      "Anticipated Next Steps": "Phase I initial data expected June 2020; Phase II/III trials start July/August 2020",
      "Product Description": "DNA plasmid vaccine with electroporation; INO-4800",
      "Clinical Trials for COVID-19": "NCT04336410",
      "Funder": "Coalition for Epidemic Preparedness (CEPI) / Gates Foundation / US Department of Defense",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for Lassa, Nipah, HIV, Filovirus, HPV, cancer indications, Zika, and Hepatitis B",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/28/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed08770354bb557e0ba03aa"
    },
    {
      "Developer / Researcher": "BioNet Asia",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "DNA-based",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "DNA",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "4/20/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed08777c974c2bb9db82ace"
    },
    {
      "Developer / Researcher": "Entos Pharmaceuticals",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "DNA-based",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "DNA",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/4/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed08766a061fe9d46f41c63"
    },
    {
      "Developer / Researcher": "Immunomic Therapeutics / EpiVax / PharmaJet",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "DNA-based",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "DNA plasmid, needle-free delivery",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for SARS",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087f10c92245c6dff6134"
    },
    {
      "Developer / Researcher": "OPENCORONA - Cobra Biologics / Karolinska Institute",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "DNA-based",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "Phase I to start in 2020",
      "Product Description": "DNA with electroporation",
      "Clinical Trials for COVID-19": "",
      "Funder": "European Commission (Horizon 2020 Program)",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/19/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087c59a43e64e58b092f5"
    },
    {
      "Developer / Researcher": "Osaka University / AnGes / Takara Bio",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "DNA-based",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "DNA plasmid",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed0877aa061fe3407f41c65"
    },
    {
      "Developer / Researcher": "Scancell/ University of Nottingham",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "DNA-based",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "Phase I to start in Q1 2021",
      "Product Description": "DNA",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for cancer",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "4/28/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed08772b051499fc3cbcf85"
    },
    {
      "Developer / Researcher": "Symvivo",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "DNA-based",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "bacTRL-Spike",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/12/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087ce0c92244162ff6133"
    },
    {
      "Developer / Researcher": "Takis / Applied DNA Sciences / Evvivax",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "DNA-based",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "Animal results released in May 2020; Phase I to start in fall 2020",
      "Product Description": "DNA",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/10/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed087763b91857832d7058a"
    },
    {
      "Developer / Researcher": "University of Waterloo",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "DNA-based",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "DNA",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "4/20/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed08799c974c22e65b82acf"
    },
    {
      "Developer / Researcher": "Zydus Cadila",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "DNA-based",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "DNA plasmid",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087e53b91854dc1d7058e"
    },
    {
      "Developer / Researcher": "Beijing Institute of Biological Products/ Sinopharm",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Inactivated virus",
      "Stage of Development": "Phase I",
      "Anticipated Next Steps": "Phase I/II started in May 2020",
      "Product Description": "Inactivated",
      "Clinical Trials for COVID-19": "ChiCTR2000032459",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/19/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087b0af02efb7f737f0a5"
    },
    {
      "Developer / Researcher": "Institute of Medical Biology, Chinese Academy of Medical Sciences",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Inactivated virus",
      "Stage of Development": "Phase I",
      "Anticipated Next Steps": "",
      "Product Description": "Inactivated",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/27/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087cc7b7f687f2733c6c0"
    },
    {
      "Developer / Researcher": "Sinovac",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Inactivated virus",
      "Stage of Development": "Phase I",
      "Anticipated Next Steps": "Phase I/II started in April 2020",
      "Product Description": "Inactivated (inactivated + alum); PiCoVacc",
      "Clinical Trials for COVID-19": "NCT04352608 NCT04383574",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for SARS",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/21/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087add6ab3654ffb31ded"
    },
    {
      "Developer / Researcher": "Wuhan Institute of Biological Products/ Sinopharm",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Inactivated virus",
      "Stage of Development": "Phase I",
      "Anticipated Next Steps": "Phase I started in May 2020",
      "Product Description": "Inactivated",
      "Clinical Trials for COVID-19": "ChiCTR2000031809",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/4/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087a661ebbf4a8dac8f47"
    },
    {
      "Developer / Researcher": "Beijing Minhai Biotechnology Co., Ltd.",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Inactivated virus",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Inactivated",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/27/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed0878af88f8debea2b272d"
    },
    {
      "Developer / Researcher": "Osaka University / BIKEN / NIBIOHN",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Inactivated virus",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Inactivated",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087acfe5ee9428261893a"
    },
    {
      "Developer / Researcher": "Research Institute for Biological Safety Problems, Republic of Kazakhstan",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Inactivated virus",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Inactivated",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/19/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed08797cc961a5297479573"
    },
    {
      "Developer / Researcher": "Sinovac/ Dynavax",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Inactivated virus",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Inactivated (inactivated + CpG 1018)",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "4/28/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087d035e57798d92d3587"
    },
    {
      "Developer / Researcher": "Valneva/ Dynavax",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Inactivated virus",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "VLA2001, Inactivated + CpG 1018",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for Japanese Encephalitis",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/12/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087cd9a43e621bbb092f6"
    },
    {
      "Developer / Researcher": "Codagenix / Serum Institute of India",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Live attenuated virus",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "Animal data in summer 2020",
      "Product Description": "Codon deoptimized live attenuated virus",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for HAV, InfA, ZIKV, FMD, SIV, RSV, DENV",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "4/28/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed08762f5757c0d55d77a98"
    },
    {
      "Developer / Researcher": "DZIF - German Center for Infection Research",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Live attenuated virus",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Live attenuated virus, measles virus (S, N targets)",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for Zika, H7N9, CHIKV",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/12/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087b8a343c6c7a3e1e257"
    },
    {
      "Developer / Researcher": "Indian Immunologicals Ltd/ Griffith University",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Live attenuated virus",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Codon deoptimized live attenuated virus",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "4/28/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087a9d7d506467eb95e82"
    },
    {
      "Developer / Researcher": "CanSino Biologics/Beijing Institute of Biotechnology/ Canada's National Research Council",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Non-replicating viral vector",
      "Stage of Development": "Phase II",
      "Anticipated Next Steps": "Phase II started April 2020; initial results released May 2020",
      "Product Description": "Non-replicating viral vector; Adenovirus Type 5 vector (Ad5-nCoV)",
      "Clinical Trials for COVID-19": "NCT04313127 ChiCTR2000030906 ChiCTR2000031781",
      "Funder": "",
      "Published Results": "The Lancet (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31208-3/fulltext)",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for EBOV",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/28/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed0878ecb4102db7b84a395"
    },
    {
      "Developer / Researcher": "Consortium of the Jenner Institute, Oxford Biomedica, University of Oxford, Vaccines Manufacturing and Innovation Centre, Pall Life Sciences, Cobra Biologics, HalixBV, Advent s.r.l., Merck KGaA, the Serum Institute, Vaccitech, and AstraZeneca",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Non-replicating viral vector",
      "Stage of Development": "Phase I",
      "Anticipated Next Steps": "Phase I/II began April 2020, data expected in May 2020; Phase II/III trials enrolling May 2020",
      "Product Description": "Non-replicating viral vector; AZD 1222 (formerly ChAdOx1)",
      "Clinical Trials for COVID-19": "NCT04324606",
      "Funder": "Coalition for Epidemic Preparedness Innovations (CEPI) / UK Government / Biomedical Advanced Research and Development Authority (BARDA)",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for influenza, TB, Chikungunya, Zika, MenB, plague",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/28/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087ebb05149d1d4cbcf8c"
    },
    {
      "Developer / Researcher": "Altimmune / University of Alabama at Birmingham",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Non-replicating viral vector",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "Phase I trial to begin Q3 2020",
      "Product Description": "AdCOVID; single-dose, intranasal vaccine; non replicating viral vector; adenovirus-based NasoVAX expressing spike protein",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for influenza",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087d2d7d5060492b95e83"
    },
    {
      "Developer / Researcher": "Bharat Biotech/ Thomas Jefferson University",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Non-replicating viral vector",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Recombinant deactivated rabies virus containing S1",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/4/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087e1354bb58f28ba03b0"
    },
    {
      "Developer / Researcher": "Centro Nacional Biotecnologia (CNB-CSIC), Spain",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Non-replicating viral vector",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Non-replicating viral vector, MVA expressing structural proteins",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for HIV, HCV, CHIKV, EBOV, Zika, Malaria, Leishmania",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087a0d504981689eb05b5"
    },
    {
      "Developer / Researcher": "DZIF - German Center for Infection Research",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Non-replicating viral vector",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Non-replicating viral vector; MVA-S encoded",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for many pathogens",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "4/20/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087c1fe5ee912ac61893b"
    },
    {
      "Developer / Researcher": "GeoVax / BravoVax",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Non-replicating viral vector",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Non-replicating viral vector; MVA encoded VLP",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for LASV, EBOV, MARV, HIV",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087d6853b9cbd406bc665"
    },
    {
      "Developer / Researcher": "Greffex",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Non-replicating viral vector",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Non-replicating viral vector; Ad5 S (GREVAXâ„¢ platform)",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for MERS",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087a2af34d420eacbab92"
    },
    {
      "Developer / Researcher": "ImmunityBio / NantKwest",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Non-replicating viral vector",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Non-replicating viral vector; Ad5",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087b5a0a6f3f4e63173b7"
    },
    {
      "Developer / Researcher": "Janssen Pharmaceutical Companies/Beth Israel Deaconess Medical Center / Emergent BioSolutions/ Catalent",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Non-replicating viral vector",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "Start Phase I in September 2020",
      "Product Description": "Non-replicating viral vector; Ad26 (alone or with MVA boost)",
      "Clinical Trials for COVID-19": "",
      "Funder": "Biomedical Advanced Research and Development Authority (BARDA)",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for Ebola, HIV, RSV",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "4/30/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed08795f5757cd741d77a9c"
    },
    {
      "Developer / Researcher": "ReiThera/ Leukocare/ Univercells",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Non-replicating viral vector",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "Start Phase I in summer 2020",
      "Product Description": "Non-replicating viral vector; replication defective simian adenovirus (GRAd) encoding SARS-CoV-2 S",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/19/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087cf4e7c23c474c6b828"
    },
    {
      "Developer / Researcher": "Stabilitech Biopharma Ltd",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Non-replicating viral vector",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Oral Ad5 S",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/4/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087ea204d2570071f26bf"
    },
    {
      "Developer / Researcher": "University of Georgia/ University of Iowa",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Non-replicating viral vector",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Non-replicating viral vector; parainfluenza virus 5 (PIV5)-based vaccine expressing the spike protein",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for MERS",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "4/28/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed0876eabaeb32baf9cda70"
    },
    {
      "Developer / Researcher": "University of Manitoba",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Non-replicating viral vector",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Non-replicating viral vector; dendritic cell-based vaccine",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "4/20/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087b39a43e6b801b092f4"
    },
    {
      "Developer / Researcher": "Valo Therapeutics Ltd",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Non-replicating viral vector",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Adenovirus-based + HLA-matched peptides (Pan-Corona)",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/4/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087bdcdf5b7ffce05a848"
    },
    {
      "Developer / Researcher": "Vaxart / Emergent BioSolutions",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Non-replicating viral vector",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "Phase I trial to begin in the second half of 2020",
      "Product Description": "Non-replicating viral vector; Oral Vaccine\n platform",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for InfA, CHIKV, LASV, NORV, EBOV, RVF, HBV, VEE",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087a4af34d40b70cbab93"
    },
    {
      "Developer / Researcher": "Novavax / Emergent BioSolutions / Praha Vaccines / Serum Institute of India",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Phase I",
      "Anticipated Next Steps": "Phase I/II started May 2020; top-line data expected July 2020",
      "Product Description": "Protein subunit; NVX-CoV2373; Full length recombinant SARS COV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M",
      "Clinical Trials for COVID-19": "NCT04368988",
      "Funder": "Coalition for Epidemic Preparedness (CEPI)",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for RSV, CCHF, HPV, VZV, EBOV",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/28/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed0879dd7d506f9a9b95e81"
    },
    {
      "Developer / Researcher": "AJ Vaccines",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Protein subunit; S protein",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed0877cf5757cd6f5d77a9b"
    },
    {
      "Developer / Researcher": "Anhui Zhifei Longcom Biopharmaceutical/ Institute of Microbiology, Chinese Academy of Sciences",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Adjuvanted recombinant protein (RBD-Dimer)",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/19/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed08768b051496360cbcf83"
    },
    {
      "Developer / Researcher": "AnyGo Technology",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Protein subunit, recombinant S1-Fc fusion protein",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/4/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087f1441a6f26c78dc3da"
    },
    {
      "Developer / Researcher": "Applied Biotechnology Institute, Inc.",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Orally delivered, heat stable subunit",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/12/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087b4a061fe4b70f41c6a"
    },
    {
      "Developer / Researcher": "Axon Neuroscience SE",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Peptides derived from Spike protein",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/12/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed0877b53c36d292780038f"
    },
    {
      "Developer / Researcher": "Baylor College of Medicine",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Protein subunit; S1 or RBD protein",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for SARS",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087d7af0b39f7640783f3"
    },
    {
      "Developer / Researcher": "Biological E Ltd",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Protein subunit; adjuvanted protein subunit (RBD)",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087b67b7f68ae8e33c6be"
    },
    {
      "Developer / Researcher": "BiOMVis Srl/ University of Trento",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "OMV-based vaccine",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/12/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087ed81f4ec89a5095f2f"
    },
    {
      "Developer / Researcher": "Clover Biopharmaceuticals Inc. / GSK / Dynavax",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "Phase I to start by mid-2020",
      "Product Description": "Protein subunit, native like trimeric subunit spike protein",
      "Clinical Trials for COVID-19": "",
      "Funder": "Coalition for Epidemic Preparedness (CEPI)",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for HIV, RSV, Influenza",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/12/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087f353c36dccbe800395"
    },
    {
      "Developer / Researcher": "EpiVax",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Protein subunit EPV-CoV-19",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/27/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed0877fb0514910e7cbcf87"
    },
    {
      "Developer / Researcher": "EpiVax / University of Georgia",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Protein subunit; S protein",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for Inf H7N9",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087db53c1352af9b755ef"
    },
    {
      "Developer / Researcher": "ExpreS2ion",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Protein subunit, drosophila S2 insect cell expression system VLPs",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed087894e7c23ddb2c6b827"
    },
    {
      "Developer / Researcher": "FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Protein subunit; peptide vaccine",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for Ebola",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed08788cb4102747984a394"
    },
    {
      "Developer / Researcher": "FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Protein subunit; subunit vaccine",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "4/28/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087d83b918501f2d7058d"
    },
    {
      "Developer / Researcher": "Flow Pharma",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Protein subunit, peptide",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for Ebola, Marburg, HIV, Zika, Influenza, HPV therapeutic vaccine, Breast Cancer",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed0877b0fce9b13d276ee7b"
    },
    {
      "Developer / Researcher": "Generex / EpiVax",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Protein subunit; Ii-Key peptide",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for HIV, SARS-CoV, Influenza",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed08786af34d44075cbab90"
    },
    {
      "Developer / Researcher": "Heat Biologics (Zolovax) / University of Miami",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Protein subunit (gp-96 backbone)",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for cancer (NSCLC), HIV, malaria, Zika",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087e9cdf5b7bae305a84a"
    },
    {
      "Developer / Researcher": "iBio / CC-Pharming",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Protein subunit; Subunit protein, plant produced",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087ee0fce9bce8e76ee81"
    },
    {
      "Developer / Researcher": "IMV, Inc., Canadian Center for Vaccinology at Dalhousie University, Izaak Walton Killam Health Center, Nova Scotia Health Authority, Canadian Immunization Research Network, University of Laval, Global Urgent and Advanced Research and Development in Canada",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "Start Phase I testing by summer 2020",
      "Product Description": "Protein subunit; DPX-COVID-19, protein subunit, peptide antigens formulated in LNP",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for cancer and infectious diseases, including malaria and anthrax",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/21/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed08784a061fea0a1f41c68"
    },
    {
      "Developer / Researcher": "Innovax / Xiamen University / GSK",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Protein subunit; COVID-19 XWG-03 truncated Spike proteins",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for HPV",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087bb7b7f68cc0a33c6bf"
    },
    {
      "Developer / Researcher": "Intravacc/Epivax",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Outer Membrane Vesicle (OMV)-peptide",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/19/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087cce2c2193c1eaae741"
    },
    {
      "Developer / Researcher": "Kentucky\n  BioProcessing (British American Tobacco)",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "RBD-based",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/27/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087c2a0a6f369963173b8"
    },
    {
      "Developer / Researcher": "LakePharma, Inc.",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Protein subunit, nanoparticle vaccine",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/4/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087e8af02efa25c37f0a6"
    },
    {
      "Developer / Researcher": "Lomonosov Moscow State University",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Structurally modified spherical particles of the tobacco mosaic virus (TMV)",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/27/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087e0abaeb304829cda75"
    },
    {
      "Developer / Researcher": "Medigen Vaccine Biologics Corp/ NIAID/ Dynavax",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "S-2 P protein + CpG 1018",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/12/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087c953c36d5cd7800392"
    },
    {
      "Developer / Researcher": "MIGAL Galilee Research Institute",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Protein subunit; oral E. coli-based protein expression system of S and N proteins",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087a3a0a6f3ccd83173b6"
    },
    {
      "Developer / Researcher": "National Institute of Infectious Disease, Japan",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Protein subunit, S protein + adjuvant",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for Influenza",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087c6b051492729cbcf8b"
    },
    {
      "Developer / Researcher": "Neovii/Tel Aviv University",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "RBD-based",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/19/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087caabaeb3fccb9cda72"
    },
    {
      "Developer / Researcher": "OncoGen",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Protein subunit, synthetic long peptide vaccine candidate for S and M proteins",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087bcaf0b3968b90783f1"
    },
    {
      "Developer / Researcher": "Osaka University / BIKEN / National Institutes of Biomedical Innovation, Japan",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Protein subunit, VLP-recombinant protein + adjuvant",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087c453c1357238b755ee"
    },
    {
      "Developer / Researcher": "PREVENT-nCoV consortium (AdaptVac, Institute for Tropical Medicine at University of Tubingen, Leiden University Medical Center, University of Copenhagen, ExpreS2ion Biotechnologies, Wageningen University)/ Bavarian Nordic",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "Phase I to begin by February 2021",
      "Product Description": "Protein subunit, capsid-like particle (CLP)",
      "Clinical Trials for COVID-19": "",
      "Funder": "European Commission (Horizon 2020 Program)",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for HPV",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/14/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed08782a061fed62df41c67"
    },
    {
      "Developer / Researcher": "Quadram Institute Biosciences",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "OMV-based vaccine",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for Flu A, plaque",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/12/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed0878b1034dc0a85eba2df"
    },
    {
      "Developer / Researcher": "Sanofi Pasteur / GSK",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "Phase I/II to start in September 2020",
      "Product Description": "Protein subunit; S protein, baculovirus production",
      "Clinical Trials for COVID-19": "",
      "Funder": "Biomedical Advanced Research and Development Authority (BARDA)",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for Influenza, SARS-CoV (FDA approved vaccine)",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/8/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087c7af0b3922550783f2"
    },
    {
      "Developer / Researcher": "St. Petersburg Scientific Research Institute of Vaccines and Serums",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Protein subunit, recombinant protein, nanoparticles (based on S-protein and other epitopes)",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087e7e2c219921faae742"
    },
    {
      "Developer / Researcher": "UMN Pharma (Shionogi)",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "Phase I to start by end of 2020",
      "Product Description": "Protein subunit; recombinant protein vaccine, utilizing baculovirus expression vector system technology",
      "Clinical Trials for COVID-19": "",
      "Funder": "Japan Agency for Medical Research and Development",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/10/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed08780a061fe014bf41c66"
    },
    {
      "Developer / Researcher": "University of Alberta",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Protein subunit; spike based",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for Hepatitis C",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087d3abaeb3c5899cda73"
    },
    {
      "Developer / Researcher": "University of California, San Diego",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Protein subunit; plant virus nanotechnology formulated as injectable and microneedle patch",
      "Clinical Trials for COVID-19": "",
      "Funder": "National Science Foundation (Rapid Response Research [RAPID] grant)",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "4/28/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087c8f5757cb7b7d77a9e"
    },
    {
      "Developer / Researcher": "University of Cambridge / DIOSynVax",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "Phase I to start as early as June 2020",
      "Product Description": "Protein subunit; S protein",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Influenza, Ebola",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed08793cc961a2f95479572"
    },
    {
      "Developer / Researcher": "University of Pittsburgh",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "Phase I to start as early as June 2020",
      "Product Description": "PittCoVacc, Protein subunit, microneedle arrays S1 subunit",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for MERS",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087bdb05149301acbcf89"
    },
    {
      "Developer / Researcher": "University of Queensland / GSK / Dynavax",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Protein subunit; molecular clamp stabilized Spike protein",
      "Clinical Trials for COVID-19": "",
      "Funder": "Coalition for Epidemic Preparedness (CEPI)/Queensland Government/Federal Government (Australia)/Paul Ramsay Foundation",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for Nipah, influenza, Ebola, Lassa",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087dc354bb53305ba03ae"
    },
    {
      "Developer / Researcher": "Vabiotech",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Protein subunit, recombinant S protein in IC-BEVS",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/4/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed0877dd6ab36e64cb31dea"
    },
    {
      "Developer / Researcher": "Vaxil Bio",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Protein subunit; peptide",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed0876af5757c0effd77a9a"
    },
    {
      "Developer / Researcher": "Vaxine Pty Ltd / Flinders University / Oracle",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Protein subunit; recombinant spike protein with Advax adjuvant",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "4/28/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087943b9185fd2dd7058b"
    },
    {
      "Developer / Researcher": "VIDO-InterVac, University of Saskatchewan",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "Animal testing results expected in April 2020",
      "Product Description": "Protein subunit, adjuvanted microsphere peptide",
      "Clinical Trials for COVID-19": "",
      "Funder": "The Government of Saskatchewan and the Canadian Federal Government",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed08791cb410297a884a396"
    },
    {
      "Developer / Researcher": "WRAIR / USAMRIID",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Protein subunit; S protein",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087ab0c922494f2ff6132"
    },
    {
      "Developer / Researcher": "Yisheng Biopharma",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Protein subunit",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Protein subunit, recombinant protein",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/4/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed0876d204d250c301f26bc"
    },
    {
      "Developer / Researcher": "BIOCAD / IEM",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Replicating viral vector",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Replicating viral vector, live viral vectored vaccine based on attenuated influenza virus backbone (intranasal)",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087aac974c29c37b82ad0"
    },
    {
      "Developer / Researcher": "FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Replicating viral vector",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Replicating viral vector; measles vector",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "4/28/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087ecfe5ee92e2961893c"
    },
    {
      "Developer / Researcher": "FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Replicating viral vector",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Replicating viral vector; VSV vector",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "4/28/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087d1af34d49205cbab94"
    },
    {
      "Developer / Researcher": "FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Replicating viral vector",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Replicating viral vector, recombinant vaccine based on Influenza A virus, for the prevention of COVID-19 (intranasal)",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for influenza",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "4/28/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed08771a343c6dfcde1e255"
    },
    {
      "Developer / Researcher": "Fundacao Oswaldo Cruz and Instituto Buntantan",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Replicating viral vector",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Attenuated Influenza expressing an antigenic portion of the Spike protein",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/27/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087e553c36d669c800393"
    },
    {
      "Developer / Researcher": "IAVI / Batavia/ Merck",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Replicating viral vector",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "Clinical studies to start in 2020",
      "Product Description": "Replicating viral vector, replication-competent VSV chimeric virus technology (VSVdeltaG) delivering the SARS-CoV-2 Spike (S) glycoprotein",
      "Clinical Trials for COVID-19": "",
      "Funder": "Biomedical Advanced Research and Development Authority (BARDA)",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for Ebola, Marburg, Lassa (including FDA-licensed Ebola vaccine, ERVEBOÂ®)",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/28/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed0879c3b9185d95cd7058c"
    },
    {
      "Developer / Researcher": "Institut Pasteur / Themis / University of Pittsburgh / Merck",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Replicating viral vector",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "Start animal testing in April 2020; clinical testing to start later in 2020",
      "Product Description": "Replicating viral vector; measles vector",
      "Clinical Trials for COVID-19": "",
      "Funder": "Coalition for Epidemic Preparedness (CEPI)",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for West nile, CHIKV, Ebola, Lassa, Zika, MERS",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/28/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed08765f88f8d88252b272a"
    },
    {
      "Developer / Researcher": "Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ.",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Replicating viral vector",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Newcastle disease virus vector (NDV-SARS-CoV-2/Spike)",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/19/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed0876cb05149b4d5cbcf84"
    },
    {
      "Developer / Researcher": "KU Leuven",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Replicating viral vector",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Replicating viral vector; YF17D Vector",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/4/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed08783a343c6b93fe1e256"
    },
    {
      "Developer / Researcher": "The Lancaster University, UK",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Replicating viral vector",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Avian paramyxovirus vector (APMV)",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/19/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087c4cb4102384b84a397"
    },
    {
      "Developer / Researcher": "The University of Hong Kong",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Replicating viral vector",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Replicating viral vector, influenza vector expressing RBD",
      "Clinical Trials for COVID-19": "",
      "Funder": "Coalition for Epidemic Preparedness (CEPI)",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for MERS",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087de354bb53a49ba03af"
    },
    {
      "Developer / Researcher": "Tonix Pharma / Southern Research",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Replicating viral vector",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Replicating viral vector; horsepox vector expressing S protein; TNX-1800",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for smallpox, monkeypox",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/19/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed08775204d2583d31f26bd"
    },
    {
      "Developer / Researcher": "University of Western Ontario",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Replicating viral vector",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Replicating viral vector; VSV-S",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for HIV, MERS",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087af1034dcc735eba2e0"
    },
    {
      "Developer / Researcher": "University of Wisconsin-Madison / FluGen/ Bharat Biotech",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Replicating viral vector",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "Start Phase I trial in fall 2020",
      "Product Description": "M2-deficient single replication (M2SR) influenza vector",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for influenza",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/4/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed0878c53c36df77c800390"
    },
    {
      "Developer / Researcher": "Zydus Cadila",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Replicating viral vector",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Replicating viral vector; measles vector",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed0879a354bb5b1daba03ad"
    },
    {
      "Developer / Researcher": "BioNTech / Fosun Pharma / Pfizer",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "RNA-based vaccine",
      "Stage of Development": "Phase I",
      "Anticipated Next Steps": "Phase I/II started April 2020; first data expected end of June or July 2020",
      "Product Description": "3 LNP-mRNAs; BNT162",
      "Clinical Trials for COVID-19": "EudraCT 2020-001038-36\n\nNCT04368728",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/19/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087df0fce9b61ba76ee7f"
    },
    {
      "Developer / Researcher": "Moderna/NIAID/Lonza",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "RNA-based vaccine",
      "Stage of Development": "Phase I",
      "Anticipated Next Steps": "Phase I ongoing; Phase II to start May 2020; Phase III to start early summer 2020; FDA granted fast track designation May 2020; initial Phase I data released May 18, 2020",
      "Product Description": "RNA; LNP-encapsulated mRNA (mRNA 1273)",
      "Clinical Trials for COVID-19": "NCT04283461",
      "Funder": "Coalition for Epidemic Preparedness (CEPI)/ Biomedical Advanced Research and Development Authority (BARDA)",
      "Published Results": "Moderna (https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-interim-phase-1-data-its-mrna-vaccine)",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for multiple candidates",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/19/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087a00fce9b9c2a76ee7d"
    },
    {
      "Developer / Researcher": "Arcturus/Duke-NUS/ Catalent",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "RNA-based vaccine",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "Start Phase 1 in summer 2020",
      "Product Description": "LUNAR-COV19; RNA; mRNA",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for multiple candidates",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/5/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed08796a061fe2005f41c69"
    },
    {
      "Developer / Researcher": "BIOCAD",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "RNA-based vaccine",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "Animal studies begin in April 2020",
      "Product Description": "RNA; liposome-encapsulated mRNA",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for cancer",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087b961ebbf6cb4ac8f49"
    },
    {
      "Developer / Researcher": "CanSino Biologics/Precision Nanosystems",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "RNA-based vaccine",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "RNA; mRNA lipid nanoparticle (mRNA-LNP)",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/21/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087ae08ef643b238bf62f"
    },
    {
      "Developer / Researcher": "Centro Nacional Biotecnologia (CNB-CSIC), Spain",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "RNA-based vaccine",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "RNA; Replicating defective SARS-CoV-2 derived RNAs",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087e235e57778672d3588"
    },
    {
      "Developer / Researcher": "China CDC / Tongji University / Stermina",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "RNA-based vaccine",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "RNA; mRNA",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed0879e204d2510ea1f26be"
    },
    {
      "Developer / Researcher": "CureVac",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "RNA-based vaccine",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "Start Phase I/IIa trial June 2020",
      "Product Description": "RNA; mRNA",
      "Clinical Trials for COVID-19": "",
      "Funder": "Coalition for Epidemic Preparedness (CEPI); European Commission; Gates Foundation; Defense Advanced Research Projects Agency (DARPA)",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for RABV, LASV, YFV, MERS, InfA, ZIKV, DengV, NIPV",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/19/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed0878f53c36d0820800391"
    },
    {
      "Developer / Researcher": "eTheRNA Immunotherapies / EpiVax/ Nexelis/ REPROCELL / Centre for the Evaluation of Vaccination of the University of Antwerp",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "RNA-based vaccine",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "Start Phase I early 2021",
      "Product Description": "RNA; mRNA in an intranasal delivery system (cross-strain protective COV-2 mRNA) vaccine for high-risk populations",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/4/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed08767a061fe4307f41c64"
    },
    {
      "Developer / Researcher": "FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "RNA-based vaccine",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "RNA; mRNA",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "4/28/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed08790abaeb31be69cda71"
    },
    {
      "Developer / Researcher": "Fudan University / Shanghai JiaoTong University / RNACure Biopharma",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "RNA-based vaccine",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "RNA; LNP-encapsulated mRNA cocktail encoding VLP",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed08774f88f8d75442b272c"
    },
    {
      "Developer / Researcher": "Fudan University / Shanghai JiaoTong University / RNACure Biopharma",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "RNA-based vaccine",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "RNA; LNP-encapsulated mRNA cocktail encoding RBD",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087d4af34d4dad2cbab95"
    },
    {
      "Developer / Researcher": "GeneOne Life Science / Houston Methodist",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "RNA-based vaccine",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "RNA",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087eecb410255be84a398"
    },
    {
      "Developer / Researcher": "Greenlight Biosciences",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "RNA-based vaccine",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "mRNA",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/12/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087d5cc961a855b479575"
    },
    {
      "Developer / Researcher": "Imperial College London",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "RNA-based vaccine",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "Start Phase I in summer 2020",
      "Product Description": "RNA; saRNA",
      "Clinical Trials for COVID-19": "",
      "Funder": "UK Government",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for EBOV, LASV, MARV, Inf (H7N9), RABV",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "4/23/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087c0b0514912d1cbcf8a"
    },
    {
      "Developer / Researcher": "RNAimmune, Inc.",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "RNA-based vaccine",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "RNA; several mRNA candidates",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/4/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087dd61ebbf603dac8f4a"
    },
    {
      "Developer / Researcher": "Sanofi Pasteur / Translate Bio",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "RNA-based vaccine",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "Phase I to start Q4 2020",
      "Product Description": "LNP-mRNA",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/28/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed087851034dcd4adeba2de"
    },
    {
      "Developer / Researcher": "University of Tokyo / Daiichi-Sankyo",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "RNA-based vaccine",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "RNA; LNP-encapsulated mRNA",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for MERS",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed08763d7d506b11ab95e80"
    },
    {
      "Developer / Researcher": "Ziphius Therapeutics/ Ghent University",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "RNA-based vaccine",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "RNA; ZIP-1642, vaccine consists of a combination of mRNA molecules, encoding multiple SARS-CoV-2 antigens",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "4/28/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087b216f25ab7c93987f3"
    },
    {
      "Developer / Researcher": "ARTES Biotechnology",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Virus-like particle",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "VLP; eVLP",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for malaria",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/4/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087daabaeb352549cda74"
    },
    {
      "Developer / Researcher": "Doherty Institute",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Virus-like particle",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "VLP",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087b1c974c243a3b82ad1"
    },
    {
      "Developer / Researcher": "Imophoron Ltd / Bristol University's Max Planck Centre",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Virus-like particle",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "VLP; ADDomerTM multiepitope display",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087c2a343c609c8e1e258"
    },
    {
      "Developer / Researcher": "Medicago Inc.",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Virus-like particle",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "Start Phase I in July/August 2020; Phase II by the end of 2020",
      "Product Description": "VLP; plant-derived VLP",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for flu, rotavirus, norovirus, West Nile virus, and cancer",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/21/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087e3cdf5b736d805a849"
    },
    {
      "Developer / Researcher": "OSIVAX",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Virus-like particle",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "VLP (COVID-19 and SARS1)",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/4/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed08787354bb597faba03ac"
    },
    {
      "Developer / Researcher": "Saiba GmbH",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Virus-like particle",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "VLP; virus-like particle, based on RBD displayed on virus-like particle",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed08792d6ab364bb4b31deb"
    },
    {
      "Developer / Researcher": "University of Sao Paulo",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Virus-like particle",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "VLPs peptides/whole virus",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/19/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087d90fce9b036376ee7e"
    },
    {
      "Developer / Researcher": "VBI Vaccines / National Research Council of Canada",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Virus-like particle",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "Start Phase I testing by end of 2020",
      "Product Description": "Enveloped virus-like particle (eVLP): Pan-coronavirus vaccine candidate, targeting COVID-19, SARS, and MERS, spike protein",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccine candidates for glioblastoma, cytomegalovirus, and Zika",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "4/28/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed08773354bb5339eba03ab"
    },
    {
      "Developer / Researcher": "AbVision",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Unknown",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "AVI-205",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/13/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed08798f88f8d7caf2b272e"
    },
    {
      "Developer / Researcher": "Catholic University/ Millennium Institute of Immunology and Immunotherapy/ Technological Consortium in Clinical Molecular Biomedicine, Chile",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Unknown",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Unknown",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "4/23/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087b8b05149a6aecbcf88"
    },
    {
      "Developer / Researcher": "Covaxx",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Unknown",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "Phase I to start in summer 2020",
      "Product Description": "Unknown",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "4/21/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed0876fcb410270c684a393"
    },
    {
      "Developer / Researcher": "Emergex Vaccines/ George Mason University's National Center for Biodefense and Infectious Diseases (NCBID)",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Unknown",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Unknown",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "4/24/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087a5d6ab36024bb31dec"
    },
    {
      "Developer / Researcher": "HaloVax (Voltron Therapeutics) / The Vaccine & Immunotherapy Center at the Massachusetts General Hospital",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Unknown",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "Animal study results by October 2020",
      "Product Description": "Self-assembling vaccine (fusion protein of a heat shock protein and Avidin, with biotinylated immunogenic peptides)",
      "Clinical Trials for COVID-19": "",
      "Funder": "Analog Devices Foundation",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "4/21/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087a761ebbf8ec9ac8f48"
    },
    {
      "Developer / Researcher": "ImmunoPrecise",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Unknown",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Unknown",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087e60fce9b82b476ee80"
    },
    {
      "Developer / Researcher": "ISR Immune System Regulation",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Unknown",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "Animal study results expected in Q2 2020, Phase I begins Q4 2020",
      "Product Description": "ISR-50",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed08764f5757cd114d77a99"
    },
    {
      "Developer / Researcher": "Oragenics (Noachis Terra)/ Aragen Bioscience",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Unknown",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "Start Phase I in late 2020 or early 2021",
      "Product Description": "TerraCoV2",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/21/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed08778b0514919afcbcf86"
    },
    {
      "Developer / Researcher": "Precision Vaccines Program at Boston Children's Hospital",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Unknown",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Unknown",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed0876af88f8d3c6e2b272b"
    },
    {
      "Developer / Researcher": "Shenzhen Geno-Immune Medical Institute",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Unknown",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Artificial antigen-presenting cells modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins",
      "Clinical Trials for COVID-19": "NCT04299724",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/12/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed0878daf34d49dddcbab91"
    },
    {
      "Developer / Researcher": "Shenzhen Geno-Immune Medical Institute",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Unknown",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "LV-SMENP-DC Dendritic cells modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins; administered with antigen-specific cytotoxic T lymphocytes",
      "Clinical Trials for COVID-19": "NCT04276896",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/12/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087a8f5757c0c51d77a9d"
    },
    {
      "Developer / Researcher": "SK Biosciences",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Unknown",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "Phase I begins as early as September 2020",
      "Product Description": "Unknown",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed0879b0fce9b362f76ee7c"
    },
    {
      "Developer / Researcher": "SmartPharm Therapeutics / Sorrento Therapeutics",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Unknown",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Gene-encoded antibody vaccine, non-viral nanoparticle delivery",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed0877fcc961a82e4479571"
    },
    {
      "Developer / Researcher": "Tulane University",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Unknown",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Unknown",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:55am",
      "CMS1": "5ed087bf53c135db77b755ed"
    },
    {
      "Developer / Researcher": "Universite Laval",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Unknown",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Unknown",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed087791034dc4a5feba2dd"
    },
    {
      "Developer / Researcher": "Vir Biotechnology / GSK",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Unknown",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Unknown",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "Prior to 4/20/2020",
      "Record Update": "5/29/2020 11:54am",
      "CMS1": "5ed08769354bb548edba03a9"
    },
    {
      "Developer / Researcher": "University of California, Los Angeles (Horwitz Lab)",
      "Treatment vs. Vaccine": "Vaccine",
      "Product Category": "Replicating bacterial vector",
      "Stage of Development": "Pre-clinical",
      "Anticipated Next Steps": "",
      "Product Description": "Recombinant LVS Î”capB â€“ vectored vaccine expressing multiple SARS-CoV-2 antigens",
      "Clinical Trials for COVID-19": "",
      "Funder": "",
      "Published Results": "",
      "Clinical Trials for Other Diseases (T only) / Related Use or Platform (V only)": "Same platform as vaccines against select agents and emerging pathogens",
      "FDA-Approved Indications": "N/A",
      "Sources": "https://docs.google.com/document/d/1Y4nCJJ4njzD1wiHbufCY6gqfRmj49Qn_qNgOJD62Wik/edit",
      "Date Last Updated": "5/10/2020",
      "Record Update": "5/29/2020 11:56am",
      "CMS1": "5ed087f0e2c21934bcaae743"
    }
]